Lumida
/ANIP
⌘K
ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc

ANIP
$70.19USD↓-1.78%-1.27 today

MARKET CAP

1.6B

P/E (TTM)

8.3x

FWD P/E

7.4x

DAY RANGE

$70 – $72

52W RANGE

$70
$99

AI Summary

Stalk
TrimMedium

ANIP remains in Stage 4 decline with price below declining EMAs and a persistent Lower Highs & Lower Lows pattern, reinforcing medium-term bearish bias. RSI is near oversold but lacks reversal structure, so selling is best deferred into rallies to the declining 9-day and 20-day EMAs around the $73–$74 region. A decisive hold above the 20-day EMA would invalidate this bias.

  • ↑Q2’26 revenue $266M (+26% YoY); adjusted EBITDA $71.6M (+32% YoY)
  • ↑Cortofan gel drove $117.1M in Q2, +43% YoY, set to be ~60% of 2026 sales
  • ↓Revenue guidance trimmed to $520–540M amid below-expectation Cortofan uptake
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is a growing specialty pharmaceutical company primarily focused on developing innovative therapeutics for rare diseases and generics. With a strong emphasis on addressing unmet patient needs, ANI has carved out a significant niche in the healthcare market, especially in rare disease treatments. The company is positioned to benefit from rising demand within specialized therapeutic areas, particularly through its flagship product, Cortofan, which targets acute gouty arthritis.

Bull says

  • ↑Q2’26 revenue $266M (+26% YoY); adjusted EBITDA $71.6M (+32% YoY)
  • ↑Cortofan gel drove $117.1M in Q2, +43% YoY, set to be ~60% of 2026 sales
  • ↑Sales force grew 50% to ~180 reps, with 95% generating new patient cases
  • ↑Operating cash flow of $56.7M in Q2; net leverage ~1x EBITDA and liquidity strong
  • ↑Generics revenue of $99.1M (+10% YoY) showcases efficiency and stable cash flow
  • ↑High earnings yield, robust growth outlook, solid liquidity, manageable debt

Bear says

  • ↓Revenue guidance trimmed to $520–540M amid below-expectation Cortofan uptake
  • ↓Non-GAAP gross margin fell to 62.6% on adverse product mix
  • ↓Insurance re-verification delays risk impacting patient starts and revenue
  • ↓Smaller size vs peers may limit market share and keep valuations low
  • ↓Weak momentum and low institutional ownership dampen stock liquidity
  • ↓Rising competition and potential regulatory shifts could pressure pricing

Investment themes with ANIP

Pharmaceuticals↓ -0.48%

Drug development driving global healthcare solutions

JNJ · LLY · RPRX

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-10-2025bullish

Transcript signals

Bull points

  • We're pleased to report record first quarter results and are reiterating our full year guidance for total revenues, Cortrophin Gel revenues, adjusted EBITDA, and adjusted EPS
  • Total revenues for the first quarter were $137.4 million, an increase of 29% over the first quarter of 2023
  • Our lead rare disease asset, purified Cortrophin Gel generated $36.9 million of revenue in the quarter, a year-over-year increase of 126%

Bear points

  • Cortrophin Gel revenues were down on a sequential basis due to the typical seasonality seen with rare disease drugs. This may affect expectations for the second quarter.
  • Research and development expenses increased 77% to $10.5 million in the first quarter of 2024, primarily due to a higher level of activity associated with both ongoing and new projects, which may raise concerns about future profitability.
Read full transcript analysis ›